Welcome to the e-CCO Library!

P479: Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. R. Lichtenstein1, G. T. Moore*2,3, A. Soonasra4, C. I. Nduaka4, K. Kwok5, L. Wang6, N. Lawendy4, G. Chan4, C. Su4, E. V. Loftus Jr.7

Created: Friday, 22 February 2019, 9:41 AM
P479: Biological therapies and bio-microbial dynamics in inflammatory bowel diseases
Year: 2021
Source: ECCO'21 Virtual
Authors: Tavakoli, P.(1);Vollmer-Conna, U.(2);Hadzi-Pavlovic, D.(2);Grimm, M.C.(3);Vázquez-Campos, X.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P479: Hepcidin and the risk of malnutrition in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Dudkowiak*, K. Neubauer, E. Poniewierka

Created: Friday, 22 February 2019, 9:49 AM
P479: Quality of care and outcomes in a tertiary hospital inflammatory bowel disease (IBD) centre: Monitoring and treatment algorithms during follow-up
Year: 2018
Source: ECCO '18 Vienna
Authors:

Z. Kurti1*, S. Restellini2,3, L. Gonczi1, W. Afif2, T. Bessissow2, G. Wild2, E. Seidman2, R. Kohen2, A. Bitton2, P.L. Lakatos1,2

Created: Thursday, 21 February 2019, 9:14 AM
P479: Reliability and responsiveness of histologic disease activity indices in Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Solitano, V.(1,2,3)*;Schaeffer, D.F.(4);Hogan, M.(2);Pai, R.K.(5);Zou, G.(2,6);Pai, R.K.(7);Vande Casteele, N.(8);Parker, C.E.(2);Remillard, J.(2);Christensen, B.(9,10);Panaccione, R.(2,11);Sands, B.E.(12);D'Haens, G.(2,13);Feagan, B.G.(1,2,6);Ma, C.(2,11);Jairath, V.(1,2,6);
Created: Friday, 14 July 2023, 11:05 AM
P479: Shifting the shunters in a paediatric inflammatory bowel disease population: thiopurine dose splitting versus allopurinol and thiopurine co-therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Chadokufa S.*1,2, Baycheva M.2, Sawney T.3, Acton N.4, Sider S.1, Shah N.2, Huggett B.4, Dziubak R.2, Kiparrissi F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P479: Trends in medication use and treatment patterns in Chinese patients with Inflammatory Bowel Diseases: A multicenter cohort study from 1999 to 2020
Year: 2022
Source: ECCO'22
Authors: Yao, L.(1);Shao, B.(1);Cao, Q.(1);
Created: Friday, 11 February 2022, 3:56 PM
P480 Efficiency and safety of endoscopic balloon dilatation of ileocolonic anastomotic strictures in patients with Crohn’s disease: A multicentric retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Lukáš1, M. Kolar1, M. Vasatko1, P. Klvana2, V. Leksa3, J. Dyntr4, L. Baca5, B. Pipek5, B. Bahnikova6, S. Summerova7

Created: Thursday, 30 January 2020, 10:12 AM
P480: Assessing primary response to biologic therapy in Inflammatory Bowel Disease - ‘the when and the how?’
Year: 2021
Source: ECCO'21 Virtual
Authors: Moore, A.C.(1);Peake, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P480: Characteristics of drug-induced lupus 2° to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mañosa M.*1, Corrales G.1, Olivares D.2, Vicuña M.3, Aguas M.4, Busquets D.5, Tosca J.6, Llaό J.7, Mesonero F.8, García-Tejero I.9, Ferreiro R.10, Cabré E.1, Domènech E.1

Created: Wednesday, 20 February 2019, 10:36 AM
P480: Comparison of executive functioning profiles among adults with Crohn's disease and Ulcerative colitis
Year: 2022
Source: ECCO'22
Authors: Zelnik Yovel, D.(1);Meyer, S.(2);Richter, V.(1);Shirin, H.(1);Broide, E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P480: Effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced diarrhoea/colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Ibraheim1,2*, M. Samaan1, N. Powell1,2

Created: Thursday, 21 February 2019, 9:14 AM
P480: Goals of treatment: preferences of inflammatory bowel disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. Casellas*1, 2, C. Herrera de Guise1, V. Robles1, E. Navarro1, N. Borruel1

Created: Friday, 22 February 2019, 9:49 AM
P480: The effect of adjuvant therapy (Sinergin®) in induction and maintaining remission in mild and moderate IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Ichim*1, A. Dimitriu1, C. Gheorghe1, M. Diculescu1, B. Mateescu2, C. Cijevschi Prelipcean3, L. Gheorghe1

Created: Friday, 22 February 2019, 9:41 AM
P480: Ustekinumab Dose Intensification Is Effective in One-Third of Asian Inflammatory Bowel Disease Patients, Results From A Tertiary Inflammatory Bowel Disease Centre.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lim, C.T.(1)*;Tay, S.W.(1);Lim, G.H.(2);Salazar, E.(1);Ong, W.C.(3);Chan, W.P.W.(1);Tan, M.T.K.(1);
Created: Friday, 14 July 2023, 11:05 AM
P481 Repeated surgery for recurrent ileocolonic Crohn’s disease: does the outcome keep worsening operation after operation? A comparative study of 1224 consecutive procedures
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Colombo1, A. Frontali1, C. Baldi1, G.M.B. Lamperti1, G. Maconi2, S. Ardizzone2, D. Foschi2, G. Sampietro1

Created: Thursday, 30 January 2020, 10:12 AM
P481: Effect of anti-TNFα therapy with daily physical activity in patients with Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. A. Lucca, C. Malaguti, A. L. Cabalzar, L. A. Chebli, T. C. R. Ribeiro*, P. D. Gaburri, J. M. F. Chebli

Created: Friday, 22 February 2019, 9:49 AM
P481: Efficacy of the sequential use of a second biologic agent for Crohn’s disease treatment in a non-academic tertiary centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

Created: Friday, 22 February 2019, 9:41 AM
P481: Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project
Year: 2021
Source: ECCO'21 Virtual
Authors: Viola, A.(1);Barbieri , M.A.(2);Pisana, V.(1);Cutroneo , P.M.(3);Fries, W.(1);Spina, E.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P481: Induction treatment with subcutaneous rather than intravenous ustekinumab is associated with comparable circulating drugs levels and early clinical response
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.R. Rowan1*, G. Cullen2, H. Mulcahy2, J. Sheridan2,3, E. Ryan4, A. De Vries5, G. D'Haens6, G.A. Doherty2

Created: Thursday, 21 February 2019, 9:14 AM